A groundbreaking new trial is set to investigate whether an mRNA jab, designed to target the Epstein-Barr virus (EBV), could ...

A team from UNIGE and HUG has discovered a subgroup of immune cells particularly involved in the disease, opening the way to ...

Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus and ...

TG Therapeutics remains attractive for investors despite competition and slowing growth. Read the latest analysis on the ...

Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States ...

Multiple Sclerosis (MS) affects women far more often than men, with the current sex ratio sitting at approximately 3:1. We ...

Advances being used to treat cancer are now being applied to lupus, rheumatoid arthritis, and other disorders.

When your body's immune cells attack you instead of protecting you, today's treatments tamp down the friendly fire but they ...

Fenebrutinib shows promise as the first BTK inhibitor for both RMS and PPMS, reducing relapses and slowing disability progression. The FENhance 2 study demonstrated fenebrutinib's efficacy over ...

Teaming up with the Healey & AMG Center, Inflammasome will advance its oral ALS drug kamuvudine-9, known as K9, into early clinical testing.

Unequal global access to inflammatory bowel disease (IBD) therapies creates profound health inequities. The increasing prevalence of IBD in Western countries, driven by high incidence rates and low ...

The media personality was diagnosed with multiple sclerosis in his late 20s, with him experiencing symptoms such as numbness ...